statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Q4 2023 ReShape Lifesciences Inc Earnings Call Transcript

Completed First Surgeries With Next-Generation Lap-Band 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023; Reaffirming Commitment to Profitability Conference...

ReShape Lifesciences  Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

Patent Significantly Strengthens Intellectual Property PortfolioIRVINE, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences (Nasdaq: RSLS), the premier physician-led weight loss and...

ReShape Lifesciences  Receives Notice of Allowance for Additional U.S. Patent Related to an Intragastric Balloon System

ReShape Lifesciences Inc. (NASDAQ:RSLS  Get Free Report) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 428,700...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Short Interest Down 43.3% in March

Nevro (NYSE:NVRO  Get Free Report) and ReShape Lifesciences (NASDAQ:RSLS  Get Free Report) are both small-cap medical companies, but which is the better investment? We will compare the...

Reviewing ReShape Lifesciences (NASDAQ:RSLS) & Nevro (NYSE:NVRO)

2024 Operating Expenses Expected to Decrease by 55.4% Compared to 2023 Company Reaffirms Commitment to Profitability High Priority Search for Synergistic M&A Partner Continues IRVINE...

ReShape Lifesciences  Provides Update on 2024 Cost Reduction Plan and Reorganization to Prioritize Commercialization of Lap-Band  2.0 FLEX

FLEX Technology Designed to Enhance the Patient Experience Surgeon Training Underway for the Initial Launch of the Lap-Band 2.0 FLEX IRVINE, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- ReShape...

ReShape Lifesciences  Announces First Surgeries Utilizing Next-Generation Lap-Band  2.0 FLEX

First Time Introduction of Lap-Band 2.0 FLEX to the Next Generation of SurgeonsIRVINE, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences (Nasdaq: RSLS), the premier physician-led...

ReShape Lifesciences  Conducts Bariatric Fellows Training for its Lap-Band  System, Highlighting the Next-Generation Lap-Band  2.0 FLEX

ReShape Lifesciences, Inc. is a medical device company, which focuses on technology to treat obesity and metabolic diseases. Its portfolio includes the Lap-Band Adjustable Gastric Banding System, ReShape Marketplace, Obalon Balloon System, ReShape Vest, and Diabetes Bloc-Stim Neuromodulation device. It operates through the United States, Australia, Europe, and Rest of World geographical segments. The company was founded in December 2002 and is headquartered in San Clemente, CA.

Volume	72,827.00
52-Wk High	$2.80
52-Wk Low	$0.1414

Period	Estimated	Reported	Surprise	Result
Q4'23	-$0.88	--	--	N/A
Q3'23	-$1.62	--	--	N/A
Q2'23	-$1.79	--	--	N/A
Q1'23	-$4.21	-$1.40	66.70%	BEAT
Q4'22	-$35.56	--	--	N/A

RSLS ReShape Lifesciences Inc.

About

Feed

News

Earnings

Fundamentals